WO1996031206A3 - Flavones and coumarins as agents for the treatment of atherosclerosis - Google Patents

Flavones and coumarins as agents for the treatment of atherosclerosis Download PDF

Info

Publication number
WO1996031206A3
WO1996031206A3 PCT/US1996/004028 US9604028W WO9631206A3 WO 1996031206 A3 WO1996031206 A3 WO 1996031206A3 US 9604028 W US9604028 W US 9604028W WO 9631206 A3 WO9631206 A3 WO 9631206A3
Authority
WO
WIPO (PCT)
Prior art keywords
coumarins
flavones
atherosclerosis
treatment
agents
Prior art date
Application number
PCT/US1996/004028
Other languages
French (fr)
Other versions
WO1996031206A2 (en
Inventor
Uday Saxena
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to AU52592/96A priority Critical patent/AU5259296A/en
Publication of WO1996031206A2 publication Critical patent/WO1996031206A2/en
Publication of WO1996031206A3 publication Critical patent/WO1996031206A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Abstract

Flavones and coumarins or a pharmaceutically acceptable salt thereof are inhibitors of VCAM-1 and ICAM-1 and are thus useful in the treatment of atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection.
PCT/US1996/004028 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of atherosclerosis WO1996031206A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52592/96A AU5259296A (en) 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of athero sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41870995A 1995-04-07 1995-04-07
US08/418,709 1995-04-07

Publications (2)

Publication Number Publication Date
WO1996031206A2 WO1996031206A2 (en) 1996-10-10
WO1996031206A3 true WO1996031206A3 (en) 1996-12-12

Family

ID=23659261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004028 WO1996031206A2 (en) 1995-04-07 1996-03-25 Flavones and coumarins as agents for the treatment of atherosclerosis

Country Status (2)

Country Link
AU (1) AU5259296A (en)
WO (1) WO1996031206A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051307A1 (en) * 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US5922719A (en) * 1997-08-11 1999-07-13 Warner-Lambert Company Coumarin dopamine D4 receptor antagonists
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
JP2002512216A (en) * 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート BTK inhibitors and methods for identification and use thereof
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
FR2781153B1 (en) * 1998-07-15 2001-08-03 Lafon Labor FLAVONOID-BASED THERAPEUTIC COMPOSITION FOR USE IN THE TREATMENT OF TUMORS WITH CYTOTOXIC AGENTS
DE19845372A1 (en) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Use of catechol derivatives as proteinase inhibitors
KR20010101203A (en) * 1998-12-15 2001-11-14 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Use of a MEK Inhibitor for Preventing Transplant Rejection
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000050030A1 (en) * 1999-02-25 2000-08-31 Ted Ebendal New use
AU2001278980A1 (en) * 2000-07-21 2002-02-05 Chugai Seiyaku Kabushiki Kaisha Coumarin derivatives useful as tnfalpha inhibitors
WO2002074307A1 (en) * 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
KR20020096367A (en) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 Pharmaceutical composition for the prevention and treatment of arthritis having effect of essential treatment and a method for screening it
KR20020096368A (en) * 2001-06-19 2002-12-31 주식회사 티지 바이오텍 Mass cell production method of chondrocytes by the inhibition of de-differentiation and a method for screening it
AR038136A1 (en) 2002-01-24 2004-12-29 Merck Frosst Canada Inc CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
JP4587652B2 (en) * 2002-09-09 2010-11-24 株式会社フラバミン Novel flavonoid compounds and their use
EP1546162B1 (en) 2002-09-20 2011-06-22 Promega Corporation Luminescence-based methods and probes for measuring cytochrome p450 activity
CA2502975A1 (en) * 2002-10-22 2004-05-06 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
WO2004041279A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
WO2004105769A1 (en) * 2003-05-28 2004-12-09 Universite De Liege Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
HU229709B1 (en) 2004-04-13 2014-05-28 Incyte Corp Wilmington Piperazinyilpiperidine derivatives as chemokine receptor antagonists
EP2272973B1 (en) 2005-05-31 2015-05-27 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
US20100068238A1 (en) * 2005-07-15 2010-03-18 Nandkishore Managoli Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis
NZ566180A (en) * 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
MEP1008A (en) 2005-12-21 2010-02-10 Incyte Corp 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN1837202B (en) * 2006-04-25 2010-08-18 中国人民解放军第二军医大学 Flavonols with blood-fat-lowering effect
WO2009118338A2 (en) * 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of a polyphenolic type compound for preventing or treating a polyglutamine expansion neurodegenerative disease
CA2711103C (en) 2008-06-26 2016-08-09 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010021686A1 (en) 2008-08-18 2010-02-25 Promega Corporation Luminogenic compounds and methods to detect cytochrome p450 3a enzymes
CA2737483A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
MX2011003373A (en) * 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinone, quinolone and related analogs as sirtuin modulators.
WO2010039815A1 (en) 2008-09-30 2010-04-08 Case Western Reserve University Molecular probes for imaging of myelin
MX2011005526A (en) 2008-11-26 2011-06-06 Pfizer 3-aminocyclopentanecarboxamides as chemokine receptor modulators.
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
SG172857A1 (en) 2009-02-09 2011-08-29 Supergen Inc Pyrrolopyrimidinyl axl kinase inhibitors
RS53268B (en) 2009-02-24 2014-08-29 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
KR101892987B1 (en) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
KR20130133219A (en) 2010-12-23 2013-12-06 머크 샤프 앤드 돔 코포레이션 Quinoxalines and aza-quinoxalines as crth2 receptor modulators
WO2012151137A1 (en) 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
CN102274237B (en) * 2011-06-16 2012-12-05 成都中医药大学 Novel application of flavonoid compound
CN103763924B (en) 2011-06-17 2016-05-18 默沙东公司 As CRTH2The Cycloalkylfused tetrahydroquinoline of receptor modulators
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
JP5992049B2 (en) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション Oral immediate release formulations for substituted quinazolinones
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (en) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． Novel heterocyclic compounds as bromodomain inhibitors
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
US9840488B2 (en) * 2015-01-26 2017-12-12 Utah State University Carbon monoxide releasing molecules and associated methods
US9580452B2 (en) 2015-02-19 2017-02-28 Council Of Scientific And Industrial Research Antioxidant compound having anti atherosclerotic effect and preparation thereof
CN107530356A (en) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 For treating the composition and treatment method of complement-associated disease
KR101837690B1 (en) * 2016-04-04 2018-03-13 한국한의학연구원 Compostion for prevention or treatment restenosis comprising Alpinia officinarum Hance extracts, fractions or galangin seperated from therefrom
DE102016223763A1 (en) * 2016-11-30 2018-05-30 Beiersdorf Ag Use of 2'-methoxyflavone in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin
CN109265424B (en) * 2018-09-25 2020-08-21 天津中医药大学 Flavonoid derivative and preparation method and identification method thereof
JP2022517610A (en) 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド Heterocyclic compound salts and their use
CN115160279B (en) * 2022-07-27 2023-11-24 中国药科大学 Benzopyrone compounds, pharmaceutical compositions and uses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175808A (en) * 1967-11-24 1969-12-23 Laroche Navarron Lab Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (en) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-Alkyl(alkenyl)-substituted quercetins
EP0347864A2 (en) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Anti-atherogenic agents
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0564350A1 (en) * 1992-03-31 1993-10-06 Adir Et Compagnie 3',5'-ditertbutyl-4'-hydroxyflavones, method for their preparation and pharmaceutical compositions with an antioxidant and antivasoconstricting activity
EP0633022A2 (en) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Chondroprotective flavones

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175808A (en) * 1967-11-24 1969-12-23 Laroche Navarron Lab Improvements in or relating to new Therapeutic Composition, new Coumarin Derivatives and their process of preparation
FR2244493A1 (en) * 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE3601417A1 (en) * 1986-01-20 1987-07-23 Nattermann A & Cie 2'-Alkyl(alkenyl)-substituted quercetins
EP0347864A2 (en) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Anti-atherogenic agents
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
EP0564350A1 (en) * 1992-03-31 1993-10-06 Adir Et Compagnie 3',5'-ditertbutyl-4'-hydroxyflavones, method for their preparation and pharmaceutical compositions with an antioxidant and antivasoconstricting activity
EP0633022A2 (en) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Chondroprotective flavones

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. DE NEELING: "Coumarine bij atherosclerose", NED. TIJDSCHR. GENEESKD., vol. 119, no. 117, 26 April 1975 (1975-04-26), pages 673 - 677, XP000575659 *
Conference on "Molecular and Clinical Implications for Allergy in the 21st Century" in Nantucket, Massachusetts September 25-29, 1994 *
E. MIDDLETON ET AL.: "Quercetin inhibits lipopolysaccharide-induced expression of endothelial cell intracellular adhesion molecule-1", INT. ARCH. ALLERGY IMMUNOL., vol. 107, no. 1-3, 13 July 1995 (1995-07-13), pages 435 - 436, XP000576204 *
E. SEMPINSKA ET AL.: "Effect of flavonoids on the platelet adhesivness in repeatedly bred rats", POL. J. PHARMACOL. PHARM., vol. 29, no. 1, 1977, pages 7 - 10, XP000575657 *
H.K. NIEUWENHUIS ET AL.: "Agents interfering with the platelet-vessel wall interaction", PHARM. WEEKBL. SCI., vol. 6, no. 1, 24 February 1984 (1984-02-24), pages 27 - 31, XP000575665 *
M.E. GERRITSEN ET AL.: "Flavonoids inhibit cytokine.induced endothelial cell adhesion protein gene expression", AM. J. PATHOLOGY, vol. 147, no. 2, 2 August 1995 (1995-08-02), pages 278 - 292, XP000575649 *
S. TRANCHINA ET AL.: "Inhibition of human monocyte adhesion to endothelial cells by the coumarin derivative, chloricromene", BR. J. PHARMACOL., vol. 111, no. 2, 1994, pages 578 - 581, XP000575658 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases

Also Published As

Publication number Publication date
AU5259296A (en) 1996-10-23
WO1996031206A2 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
WO1996031206A3 (en) Flavones and coumarins as agents for the treatment of atherosclerosis
DE69534209D1 (en) Vascular endoprosthesis and device for introducing the same
AU1382299A (en) Method and apparatus for treating stenosis of the carotid artery
HUT72166A (en) Herbicides containing 4-benzoylisoxazole derivatives and process for producing the active ingredient
MX9101869A (en) CYCLOSPORINS, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND PROCEDURE FOR THE PRODUCTION OF THE SAME
EP1006960A4 (en) Comfortable orthopaedic support and the method of making the same
EP0814814A4 (en) Methods for the treatment of thrombosis
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
DE69404527T2 (en) Rolling mill and process
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
EP0636385A3 (en) Post-heart surgery cardioverting system and method.
DE69009362D1 (en) Rolling mill and rolling process.
ITTO940100A0 (en) PLANT FOR THE FORMING OF GLASS ITEMS.
DE69822676D1 (en) Rolling plant and rolling process
EP0622879A3 (en) Semiconductor laser and production method thereof.
DE69715858T2 (en) INTRAOCULAR LENSES AND THEIR PRODUCTION PROCESS
ZA988785B (en) Cobalt-based alloy article produced from the alloy and process for the manufacture thereof
EP0627709A3 (en) Method and system for the disposal of manufactured products.
EP1152762B8 (en) Use of desoxypeganine in the treatment of alzheimer's dementia
CY2427B1 (en) Use of granisetron for the treatment of post-operative nausea and vomiting.
AU4707101A (en) Method and system for online third party referral system customized to the purchaser's needs
AU6646798A (en) Method and apparatus for the destruction of articles
GR950100091A (en) Method for the treatment of plants.
HK1043953A1 (en) Improved gaming table tracking system and method
AU6210600A (en) Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG CA CN CZ EE GE HU JP KR LT LV MX NO NZ PL RO SG SI SK UA UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG CA CN CZ EE GE HU JP KR LT LV MX NO NZ PL RO SG SI SK UA UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA